NCELNewcelX Ltd.
$3.15
$0.0361
(1.10%)
Closed $3.23
$0.083
(2.57%)
After Hours
Mkt Cap$17.46M
Vol11,895.00
Fundamentals
Mkt Cap
$17.46M
Volume
-
52W High
$30.80
52W Low
$1.83
PE Ratio
-0.19
Avg. Volume
69,370.46
EPS (Annual)
-$2.16
Rev/Employee
$0.00
Earnings
-
45
Neutral Sentiment
How do you feel about NCEL?
Michel Revel Purchases 54,545 Shares of NLS Pharmaceutics (NASDAQ:NCEL) Stock
NLS Pharmaceutics Ltd. (NASDAQ:NCEL - Get Free Report) Director Michel Revel acquired 54,545 shares of the stock in a transaction on Monday, April 27th. The stock was bought at an average price of $2.75 per share, with a total value of $149,998.75. Following the completion of the acquisition, the...
MarketBeat
EXCLUSIVE: NewcelX Eyes Accelerated 2026 Execution For Diabetes Drug
NewcelX reports 2025 results, highlights NCEL-101 progress, $3.4 million financing potential, and plans accelerated execution in 2026.read more...
Benzinga
NewcelX Announces Strategic Collaboration with Eledon Pharmaceuticals to Advance NCEL-101 Program for Type 1 Diabetes
NewcelX Announces Strategic Collaboration with Eledon Pharmaceuticals to Advance NCEL-101 Program for Type 1 Diabetes NewcelX Announces Strategic Collaboration with Eledon Pharmaceuticals to Advance...
PR Newswire
NewcelX Reports Peer-Reviewed Publication Supporting Mazindol IR/SR and Advances CVR Monetization Strategy
NewcelX Reports Peer-Reviewed Publication Supporting Mazindol IR/SR and Advances CVR Monetization Strategy NewcelX Reports Peer-Reviewed Publication Supporting Mazindol IR/SR and Advances CVR...
PR Newswire
NewcelX Announces Updated Corporate Presentation Ahead of Key Spring 2026 Investor and Partnering Conferences
NewcelX Announces Updated Corporate Presentation Ahead of Key Spring 2026 Investor and Partnering Conferences NewcelX Announces Updated Corporate Presentation Ahead of Key Spring 2026 Investor and...
PR Newswire
NewcelX Announce Positive Results from International Collaborative Study Exploring Advanced Biomaterial Approaches for Stem Cell-Derived Islet Delivery in Type 1 Diabetes Without Immune Suppression
NewcelX Announce Positive Results from International Collaborative Study Exploring Advanced Biomaterial Approaches for Stem Cell-Derived Islet Delivery in Type 1 Diabetes Without Immune Suppression...
PR Newswire
NewcelX Appoints Dr. Julien Boisdron, a Swiss Big Pharma Leader in Diabetes Innovation, to Its Scientific Advisory Board
NewcelX Appoints Dr. Julien Boisdron, a Swiss Big Pharma Leader in Diabetes Innovation, to Its Scientific Advisory Board NewcelX Appoints Dr. Julien Boisdron, a Swiss Big Pharma Leader in Diabetes...
PR Newswire
NewcelX Expands Intellectual Property Footprint with Publication of DOXA Patent Application in China
NewcelX Expands Intellectual Property Footprint with Publication of DOXA Patent Application in China NewcelX Expands Intellectual Property Footprint with Publication of DOXA Patent Application in...
PR Newswire
NewcelX Strengthens Scientific Advisory Board with Appointment of Jeremy Shefner, MD, PhD, Chief Medical Officer at the Barrow Neurological Institute
NewcelX Strengthens Scientific Advisory Board with Appointment of Jeremy Shefner, MD, PhD, Chief Medical Officer at the Barrow Neurological Institute NewcelX Strengthens Scientific Advisory Board...
PR Newswire
NewcelX CEO Issues Letter to Shareholders
NewcelX CEO Issues Letter to Shareholders NewcelX CEO Issues Letter to Shareholders PR Newswire ZURICH, Nov. 4, 2025 ZURICH, Nov. 4, 2025 /PRNewswire/ -- NewcelX Ltd. (Nasdaq: NCEL), a Swiss...
PR Newswire
<
1
2
...
>
Advertisement|Remove ads.
Latest NCEL News
ViewMichel Revel Purchases 54,545 Shares of NLS Pharmaceutics (NASDAQ:NCEL) Stock
MarketBeat
EXCLUSIVE: NewcelX Eyes Accelerated 2026 Execution For Diabetes Drug
Benzinga
NewcelX Announces Strategic Collaboration with Eledon Pharmaceuticals to Advance NCEL-101 Program for Type 1 Diabetes
PR Newswire
Advertisement|Remove ads.